Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL664574 | 1.00 | PARP1 (0.72) | PARP1PARP2 | |
| SCHEMBL5622285 | 0.96 | PARP1 (0.71) | PARP1PARP2 | |
| Hydrochloric Acid SCHEMBL18614327 | 0.93 | PARP1 (0.62) | PARP1PARP2 | |
| SCHEMBL5621656 | 0.93 | PARP1 (0.62) | PARP1PARP2 | |
| SCHEMBL5621054 | 0.89 | PARP1 (0.63) | PARP1PARP2 | |
| Hydrochloric Acid SCHEMBL18614332 | 0.89 | PARP1 (0.62) | PARP1PARP2 | |
| SCHEMBL5621893 | 0.89 | PARP1 (0.67) | PARP1PARP2 | |
| Hydrochloric Acid SCHEMBL18614329 | 0.87 | PARP1 (0.56) | PARP1PARP2 | |
| SCHEMBL7706397 | 0.86 | PARP1 (0.55) | PARP1PARP2 | |
| SCHEMBL7700398 | 0.86 | PARP1 (0.55) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226909-B1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4694883-A2 | COMBINATIONS COMPRISING AN ATR INHIBITOR AND A PARP INHIBITOR AND METHODS OF USE THEREOF | Jazz Pharmaceuticals Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025019344-A2 | COMBINATIONS COMPRISING AN ATR INHIBITOR AND A PARP INHIBITOR AND METHODS OF USE THEREOF | Jazz Pharmaceuticals, Inc. (US) | 2025-01-23 | — | — | WO | disclosed |
| CN-112972684-B | Combinations of IAP inhibitors with PARP or MEK inhibitors and other chemotherapeutic agents | 苏州亚盛药业有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20230029259-A1 | COMBINATION OF IAP INHIBITORS AND PARP OR MEK INHIBITORS OR OTHER CHEMOTHERAPEUTIC AGENTS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20220304993-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| EP-3986471-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029259-A1 | COMBINATION OF IAP INHIBITORS AND PARP OR MEK INHIBITORS OR OTHER CHEMOTHERAPEUTIC AGENTS | XIAP, BIRC5, BIRC3 | PARP1 13/4885PARP2 18/4885 |
| US-20220304993-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | NQO1, HNMT, PNMT | PARP1 218/4885PARP2 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.